Literature DB >> 32911977

Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?

Philip G Tibbo1, Kyle A McKee1, Jeffrey H Meyer2, Candice E Crocker3, Katherine J Aitchison4, Raymond W Lam5, David N Crockford6.   

Abstract

A position statement developed by the Canadian Psychiatric Association's (CPA) Research Committee and approved by the CPA's Board of Directors on May 13, 2020.

Entities:  

Year:  2020        PMID： 32911977      PMCID： PMC7918871          DOI： 10.1177/0706743720945525

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN： 0706-7437            Impact factor:   4.356


  31 in total

1.  Effect of oral THC pretreatment on marijuana cue-induced responses in cannabis dependent volunteers.

Authors:  Leslie H Lundahl; Mark K Greenwald
Journal:  Drug Alcohol Depend       Date:  2015-02-11       Impact factor: 4.492

2.  Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

Authors:  Jose M Trigo; Dina Lagzdins; Jürgen Rehm; Peter Selby; Islam Gamaleddin; Benedikt Fischer; Allan J Barnes; Marilyn A Huestis; Bernard Le Foll
Journal:  Drug Alcohol Depend       Date:  2016-02-23       Impact factor: 4.492

3.  Implications of Cannabis Legalization on Youth and Young Adults.

Authors:  Phil Tibbo; Candice E Crocker; Raymond W Lam; Jeff Meyer; Jitender Sareen; Katherine J Aitchison
Journal:  Can J Psychiatry       Date:  2018-01       Impact factor: 4.356

4.  Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

Authors:  Mateus M Bergamaschi; Regina Helena Costa Queiroz; Marcos Hortes Nisihara Chagas; Danielle Chaves Gomes de Oliveira; Bruno Spinosa De Martinis; Flávio Kapczinski; João Quevedo; Rafael Roesler; Nadja Schröder; Antonio E Nardi; Rocio Martín-Santos; Jaime Eduardo Cecílio Hallak; Antonio Waldo Zuardi; José Alexandre S Crippa
Journal:  Neuropsychopharmacology       Date:  2011-02-09       Impact factor: 7.853

5.  Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.

Authors:  David J Allsop; Jan Copeland; Nicholas Lintzeris; Adrian J Dunlop; Mark Montebello; Craig Sadler; Gonzalo R Rivas; Rohan M Holland; Peter Muhleisen; Melissa M Norberg; Jessica Booth; Iain S McGregor
Journal:  JAMA Psychiatry       Date:  2014-03       Impact factor: 21.596

6.  Effect of dronabinol therapy on physical activity in anorexia nervosa: a randomised, controlled trial.

Authors:  Alin Andries; Bibi Gram; René Klinkby Støving
Journal:  Eat Weight Disord       Date:  2014-06-03       Impact factor: 4.652

7.  Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

Authors:  Ruth E Cooper; Emma Williams; Seth Seegobin; Charlotte Tye; Jonna Kuntsi; Philip Asherson
Journal:  Eur Neuropsychopharmacol       Date:  2017-05-30       Impact factor: 4.600

8.  Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Authors:  F M Leweke; D Piomelli; F Pahlisch; D Muhl; C W Gerth; C Hoyer; J Klosterkötter; M Hellmich; D Koethe
Journal:  Transl Psychiatry       Date:  2012-03-20       Impact factor: 6.222

9.  Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.

Authors:  Jose M Trigo; Alexandra Soliman; Lena C Quilty; Benedikt Fischer; Jürgen Rehm; Peter Selby; Allan J Barnes; Marilyn A Huestis; Tony P George; David L Streiner; Gregory Staios; Bernard Le Foll
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

10.  Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.

Authors:  Philip McGuire; Philip Robson; Wieslaw Jerzy Cubala; Daniel Vasile; Paul Dugald Morrison; Rachel Barron; Adam Taylor; Stephen Wright
Journal:  Am J Psychiatry       Date:  2017-12-15       Impact factor: 18.112
View more
  2 in total

1.  Response to Canadian Psychiatric Association Cannabinoid Products Position Statement: Potential for Ameliorating Cannabis Withdrawal.

Authors:  Anees Bahji
Journal:  Can J Psychiatry       Date:  2020-12-02       Impact factor: 4.356

Review 2.  Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis.

Authors:  Anees Bahji; Arthi Chinna Meyyappan; Emily R Hawken; Philip G Tibbo
Journal:  Int J Drug Policy       Date:  2021-05-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.